Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
15
10
2019
revised:
13
12
2019
accepted:
06
04
2020
pubmed:
12
4
2020
medline:
16
9
2021
entrez:
12
4
2020
Statut:
ppublish
Résumé
Emerging evidence supports a role of the receptor activator of NF-κB (RANK) pathway in normal mammary gland development and breast carcinogenesis. Osteoprotegerin (OPG) is the endogenous decoy receptor for RANK-ligand (RANKL), which inhibits RANK-signaling. Whether OPG may be a biomarker of breast cancer risk remains unclear. We evaluated the association between plasma OPG and breast cancer risk in a case ( Overall, there was no substantial evidence for an association between plasma OPG levels and breast cancer risk, although the point estimate for the highest (vs. lowest) quartile was below 1 (OR = 0.78; 95% CI, 0.46-1.33; Findings from this prospective study do not provide substantial evidence for an association between circulating OPG and breast cancer risk among premenopausal women; however, we were underpowered in stratified analyses. Results do not provide strong evidence for OPG as a potential biomarker of breast cancer risk among premenopausal women.
Sections du résumé
BACKGROUND
Emerging evidence supports a role of the receptor activator of NF-κB (RANK) pathway in normal mammary gland development and breast carcinogenesis. Osteoprotegerin (OPG) is the endogenous decoy receptor for RANK-ligand (RANKL), which inhibits RANK-signaling. Whether OPG may be a biomarker of breast cancer risk remains unclear.
METHODS
We evaluated the association between plasma OPG and breast cancer risk in a case (
RESULTS
Overall, there was no substantial evidence for an association between plasma OPG levels and breast cancer risk, although the point estimate for the highest (vs. lowest) quartile was below 1 (OR = 0.78; 95% CI, 0.46-1.33;
CONCLUSIONS
Findings from this prospective study do not provide substantial evidence for an association between circulating OPG and breast cancer risk among premenopausal women; however, we were underpowered in stratified analyses.
IMPACT
Results do not provide strong evidence for OPG as a potential biomarker of breast cancer risk among premenopausal women.
Identifiants
pubmed: 32277005
pii: 1055-9965.EPI-19-1154
doi: 10.1158/1055-9965.EPI-19-1154
pmc: PMC7269832
mid: NIHMS1584106
doi:
Substances chimiques
Osteoprotegerin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1264-1270Subventions
Organisme : NCI NIH HHS
ID : R01 CA050385
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA067262
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA176726
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176726
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA168504
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
BMC Cancer. 2015 Nov 25;15:935
pubmed: 26608463
Epidemiology. 1999 Jan;10(1):37-48
pubmed: 9888278
Nature. 2010 Jun 10;465(7299):798-802
pubmed: 20383121
Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1746-1754
pubmed: 31292137
Nature. 2010 Nov 4;468(7320):98-102
pubmed: 20881962
Clin Med Insights Endocrinol Diabetes. 2014 Jul 29;7:19-24
pubmed: 25125991
EBioMedicine. 2015 Sep 09;2(10):1331-9
pubmed: 26629528
Stat Med. 1989 May;8(5):551-61
pubmed: 2657958
Nature. 2010 Nov 4;468(7320):103-7
pubmed: 20881963
Gerontology. 2015;61(6):534-42
pubmed: 25720990
IARC Sci Publ. 1980;(32):5-338
pubmed: 7216345
Cancer Res. 2006 Feb 15;66(4):2476-82
pubmed: 16489055
Nat Med. 2016 Aug;22(8):933-9
pubmed: 27322743
Cell. 2000 Sep 29;103(1):41-50
pubmed: 11051546
BMC Med. 2017 Feb 8;15(1):26
pubmed: 28173834
Mol Cancer. 2015 Jun 10;14:117
pubmed: 26054853
Nature. 2010 Jun 10;465(7299):803-7
pubmed: 20445538
Cancer Prev Res (Phila). 2018 Dec;11(12):789-796
pubmed: 30352839
Oncotarget. 2017 Jan 17;8(3):3811-3825
pubmed: 28002811
Horm Cancer. 2018 Apr;9(2):117-127
pubmed: 29330698
Stat Med. 2016 Feb 28;35(5):782-800
pubmed: 26619806
Adv Cancer Res. 2009;103:43-73
pubmed: 19854352
Eur J Epidemiol. 2015 Mar;30(3):219-30
pubmed: 25446307
Oncotarget. 2016 Dec 27;7(52):86687-86694
pubmed: 27893411
Cancer Prev Res (Phila). 2017 Sep;10(9):525-534
pubmed: 28701332
Breast Cancer Res. 2013 Mar 06;15(2):R19
pubmed: 23497468
J Natl Cancer Inst. 1995 Nov 1;87(21):1622-9
pubmed: 7563205
Am J Epidemiol. 1992 Dec 1;136(11):1400-13
pubmed: 1488967
Breast Cancer Res. 2011 May 11;13(3):R50
pubmed: 21569367